Gregory A. Demopulos, M.D.

New Capabilities

As of May 2026: Leading company through first commercial launch

For decades, patients with transplant-associated thrombotic microangiopathy (TA-TMA) after stem cell transplants faced no FDA-approved treatment—mortality rates reached 80-90% for severe cases. In December 2025, the FDA approved Yartemlea, the first therapy for TA-TMA.

Updated May 23